A Golden Gate-based dual-expression vector enables rapid screening, which facilitates efficient isolation of high-affinity cross-reactive antibodies for therapeutic or diagnostic use and provides a ...

The company is developing new biological entities (NBEs) focusing on antibody-drug conjugates and antibody-based therapeutics ...

ANKET ® ( A ntibody-based NK cell E ngager T herapeutics) is Innate's proprietary platform for developing next-generation, multi-specific natural killer (NK) cell engagers to treat certain types of ...

Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Sutro Biopharma (STRO – Research Report), retaining the price target of ...

AbbVie ABBV announced that the European Commission (“EC”) has granted marketing authorization to Elahere (mirvetuximab ...

AbbVie (ABBV) announced the European Commission, or EC, granted marketing authorization for Elahere for the treatment of adult patients with ...

The decision in Europe follows an approval granted by the US Food and Drug Administration (FDA) in March this year.

VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...

Equities researchers at StockNews.com started coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE – Get Free Report) in a report issued on Friday. The brokerage set a “hold” rating on the ...

The rise of antibody therapeutics is transforming drug discovery, providing highly specific treatments for complex diseases ...

Researchers have created a groundbreaking antibody that combines targeting, delivery, and immune activation to treat cancer, ...

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...